Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection

Matteo Puccetti, Larissa Gomes dos Reis, Marilena Pariano, Claudio Costantini, Giorgia Renga, Maurizio Ricci, Daniela Traini, Stefano Giovagnoli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

A tryptophan metabolite of microbial origin, indole-3-carboxaldehyde (3-IAld), has been recently identified as a Janus molecule that, acting at the host-pathogen interface and activating the aryl hydrocarbon receptor, can result as a potential candidate to treat infections as well as diseases with an inflammatory and/or immune component. In this work, an inhaled dry powder of 3-IAld was developed and evaluated for its efficacy, compared to oral and intranasal administration using an aspergillosis model of infection and inflammation. The obtained inhalable dry powder was shown to: i) be suitable to be delivered for pulmonary administration, ii) possess good toxicological safety, and iii) be superior to other administration modalities (oral and intranasal) in reducing disease scores by acting on infection and inflammation. This study supports the use of 3-IAld inhalable dry powders as a potential novel therapeutic tool to target inflammation and infection in pulmonary diseases.

Original languageEnglish
Article number121004
Pages (from-to)1-11
Number of pages11
JournalInternational Journal of Pharmaceutics
Volume607
Early online date13 Aug 2021
DOIs
Publication statusPublished - 25 Sep 2021

Keywords

  • Indole-3-carboxaldehyde
  • Inflammation
  • Inhaled dry powders
  • Postbiotics
  • Pulmonary infections

Fingerprint

Dive into the research topics of 'Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection'. Together they form a unique fingerprint.

Cite this